{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:21:00Z","timestamp":1782379260692,"version":"3.54.5"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2024.103305","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T05:53:23Z","timestamp":1726120403000},"page":"103305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic potentials of adoptive cell therapy in immune-mediated neuropathy"],"prefix":"10.1016","volume":"149","author":[{"given":"Siqi","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103305_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jaut.2024.103305_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103305_bib3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103305_bib4","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jaut.2024.103305_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"Van Nes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib7","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","article-title":"Neurofascin as a target for autoantibodies in peripheral neuropathies","volume":"79","author":"Man","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.expneurol.2011.12.010","article-title":"Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: an in and ex vivo imaging study in the mouse","volume":"233","author":"Rupp","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577280","article-title":"Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155","volume":"345","author":"Jiao","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2024.103305_bib10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp-2017-315736","article-title":"IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy","volume":"88","author":"Campagnolo","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol. Commun"},{"key":"10.1016\/j.jaut.2024.103305_bib12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp-2019-322479","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barr\u00e9 syndrome","volume":"91","author":"Koike","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.0000000000006625","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in CIDP","volume":"91","author":"Koike","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","article-title":"Adoptive cell therapy targeting neoantigens: a frontier for cancer research","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102761","article-title":"Engineered antigen-specific regulatory T cells for autoimmune skin conditions","volume":"20","author":"Mukhatayev","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103305_bib16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jaut.2024.103305_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jaut.2024.103305_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jaut.2024.103305_bib19","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jaut.2024.103305_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jaut.2024.103305_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2015.00251","article-title":"B cells use conserved polarity cues to regulate their antigen processing and presentation functions","volume":"6","author":"Yuseff","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib25","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib26","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib27","doi-asserted-by":"crossref","first-page":"179ps7","DOI":"10.1126\/scitranslmed.3005568","article-title":"Cell-based therapeutics: the next pillar of medicine","volume":"5","author":"Fischbach","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2024.103305_bib29","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103305_bib30","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.4049\/jimmunol.1501761","article-title":"Early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition","volume":"198","author":"Arumugakani","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103305_bib32","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/bloodadvances.2020002435","article-title":"Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2024.103305_bib33","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaut.2024.103305_bib34","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib35","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib36","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jaut.2024.103305_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaut.2024.103305_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103305_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.jaut.2024.103305_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111239","article-title":"The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR","volume":"126","author":"Zhou","year":"2024","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.jaut.2024.103305_bib42","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103305_bib43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.jaut.2024.103305_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib46","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.jaut.2024.103305_bib47","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2024.103305_bib49","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103305_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.jaut.2024.103305_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib52","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"key":"10.1016\/j.jaut.2024.103305_bib53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/path.5585","article-title":"Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity","volume":"253","author":"Niu","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.jaut.2024.103305_bib55","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib56","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103305_bib57","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"CALM Study Group, UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2024.103305_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol. Commun"},{"key":"10.1016\/j.jaut.2024.103305_bib59","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1158\/1078-0432.CCR-20-2754","article-title":"CAR T cells targeting human immunoglobulin light chains eradicate mature B-cell malignancies while sparing a subset of normal B cells","volume":"27","author":"Ranganathan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jaut.2024.103305_bib60","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103305_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003811","article-title":"NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome","volume":"10","author":"Ishihara","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.trecan.2021.10.007","article-title":"Exploiting T cell signaling to optimize engineered T cell therapies","volume":"8","author":"Wang","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib63","first-page":"1088","article-title":"Comparison of T Cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.jaut.2024.103305_bib64","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A phase 1 trial of NY\u2010ESO \u20101\u2010specific TCR \u2010engineered T\u2010cell therapy combined with a lymph node\u2010targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jaut.2024.103305_bib65","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.jaut.2024.103305_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.jaut.2024.103305_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jaut.2024.103305_bib69","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103305_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaut.2024.103305_bib71","series-title":"CD8\u03e9 T-Cell Immunity in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","author":"Schneider-Hohendorf","year":"2012"},{"key":"10.1016\/j.jaut.2024.103305_bib72","first-page":"awad404","article-title":"Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis","author":"Ban","year":"2023","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jaut.2024.103305_bib74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib75","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103305_bib76","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.jaut.2024.103305_bib77","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2020.01603","article-title":"M1 macrophage derived exosomes aggravate experimental autoimmune neuritis via modulating Th1 response","volume":"11","author":"Du","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib78","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1159\/000430251","article-title":"Macrophage polarization modulates development of systemic lupus erythematosus","volume":"37","author":"Li","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jaut.2024.103305_bib79","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/rheumatology\/kew324","article-title":"High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells","volume":"55","author":"Schaper","year":"2016","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.jaut.2024.103305_bib80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10637-023-01344-9","article-title":"RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines","volume":"41","author":"Shang","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jaut.2024.103305_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114354","article-title":"Targeting tumor-associated macrophages as an antitumor strategy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103305_bib82","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity","volume":"10","author":"S\u00e1nchez-Paulete","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jaut.2024.103305_bib83","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cell.2023.02.004","article-title":"Apoptotic cell fragments locally activate tingible body macrophages in the germinal center","volume":"186","author":"Grootveld","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103305_bib84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.autrev.2005.01.007","article-title":"Regulatory T cells: development, function and role in autoimmunity","volume":"4","author":"Lan","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103305_bib85","article-title":"Clinical and immunological characteristics of five patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China\u2013expanding the atypical phenotypes","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jaut.2024.103305_bib87","unstructured":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/36097223\/(accessed October 16, 2023)."},{"key":"10.1016\/j.jaut.2024.103305_bib88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets \u2014 results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib89","first-page":"22","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127\u2212 T regulatory cells, Clin","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Autoimmunity centers of excellence, adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"10.1016\/j.jaut.2024.103305_bib91","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103305_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib93","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad012","article-title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration","volume":"3","author":"Mansilla","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.jaut.2024.103305_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5463879","article-title":"Immature dendritic cell therapy confers durable immune modulation in an antigen-dependent and antigen-independent manner in nonobese diabetic mice","volume":"2018","author":"Lo","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jaut.2024.103305_bib95","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jaut.2024.103305_bib96","article-title":"Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib97","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fimmu.2019.00798","article-title":"Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response","volume":"10","author":"Luque-Campos","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib98","first-page":"2072","article-title":"Cutting Edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients","volume":"187","author":"Hutchinson","year":"2011","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.jaut.2024.103305_bib99","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103032","article-title":"Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"21","author":"Hu","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103305_bib101","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ene.14133","article-title":"Antibody\u2010 and macrophage\u2010mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates","volume":"27","author":"Vallat","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116509","article-title":"Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies","volume":"408","author":"Koike","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jaut.2024.103305_bib103","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.331","article-title":"Terminal complement activation is increased and associated with disease severity in CIDP","volume":"3","author":"Quast","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib104","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jaut.2024.103305_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104205","article-title":"Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes","volume":"9","author":"Shimizu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2024.103305_bib106","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/jnnp-2018-319270","article-title":"Increased IP-10 production by blood\u2013nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy","volume":"90","author":"Shimizu","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib107","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jnnp-2013-305405","article-title":"Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier","volume":"85","author":"Shimizu","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib108","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.pain.2012.06.005","article-title":"Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis","volume":"153","author":"Austin","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.jaut.2024.103305_bib109","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib110","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103305_bib111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11910-023-01264-4","article-title":"Growing spectrum of autoimmune nodopathies","volume":"23","author":"Gupta","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jaut.2024.103305_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2017.05.002","article-title":"Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies","volume":"309","author":"Mathey","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2024.103305_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib114","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/brain\/aww062","article-title":"Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects","volume":"139","author":"Manso","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103305_bib115","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.neuron.2010.02.004","article-title":"A glial signal consisting of gliomedin and NrCAM clusters axonal Na+ channels during the formation of nodes of Ranvier","volume":"65","author":"Feinberg","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.jaut.2024.103305_bib116","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1038\/s41467-022-34302-9","article-title":"Structural insights into the contactin 1 \u2013 neurofascin 155 adhesion complex","volume":"13","author":"Chataigner","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103305_bib117","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib118","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1212\/NXI.0000000000000603","article-title":"Anti\u2013pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy","volume":"6","author":"Stengel","year":"2019","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib119","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2020","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib120","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/brain\/aww189","article-title":"Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103305_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121705","article-title":"Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody","volume":"14","author":"Bai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib122","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib123","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acn3.51775","article-title":"Clinical profile of autoimmune nodopathy with anti\u2010neurofascin 186 antibody","volume":"10","author":"Liu","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.939062","article-title":"Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ene.13838","article-title":"Obinutuzumab, a new anti\u2010CD20 antibody, and chlorambucil are active and effective in anti\u2010myelin\u2010associated glycoprotein antibody polyneuropathy","volume":"26","author":"Briani","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib126","article-title":"Case Report: ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib127","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib128","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001098","article-title":"Clinical and laboratory features in anti-nf155 autoimmune nodopathy","volume":"9","author":"Mart\u00edn-Aguilar","year":"2022","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib129","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103305_bib130","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of guillain-barr\u00e9 syndrome","author":"van Doorn","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib131","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.it.2022.02.003","article-title":"Guillain-Barr\u00e9 syndrome: expanding the concept of molecular mimicry","volume":"43","author":"Laman","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12974-021-02301-0","article-title":"Autoantibody screening in guillain\u2013barr\u00e9 syndrome","volume":"18","author":"Lleix\u00e0","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jaut.2024.103305_bib133","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib134","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1523\/JNEUROSCI.4926-14.2015","article-title":"Anti-ganglioside antibodies induce nodal and axonal injury via fc\u03b3 receptor-mediated inflammation","volume":"35","author":"He","year":"2015","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.jaut.2024.103305_bib135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-510X(03)00029-7","article-title":"Longitudinal changes of anti-ganglioside antibodies before and after Guillain-Barr\u00e9 syndrome onset subsequent to Campylobacter jejuni enteritis","volume":"210","author":"Odaka","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jaut.2024.103305_bib136","first-page":"885","article-title":"Immunoglobulin and monoclonal antibody therapies in guillain-barr\u00e9 syndrome","volume":"19","author":"Rajabally","year":"2022","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.jaut.2024.103305_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101109","article-title":"Mini-TCRs: truncated T cell receptors to generate T cells from induced pluripotent stem cells","volume":"31","author":"Takayanagi","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jaut.2024.103305_bib138","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2023.029","article-title":"Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T\/CAR-T cells","author":"Xie","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jaut.2024.103305_bib139","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jaut.2024.103305_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jaut.2024.103305_bib141","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnen\/63.2.129","article-title":"Multifocal motor neuropathy: pathologic alterations at the site of conduction block","volume":"63","author":"Taylor","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib142","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.clinph.2020.08.004","article-title":"Excitability of motor and sensory axons in multifocal motor neuropathy","volume":"131","author":"Kovalchuk","year":"2020","journal-title":"Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol."},{"key":"10.1016\/j.jaut.2024.103305_bib143","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","article-title":"Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy","volume":"85","author":"Nobile-Orazio","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib144","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/jnnp.2009.202796","article-title":"Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside","volume":"81","author":"Pestronk","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2024.103305_bib145","doi-asserted-by":"crossref","first-page":"11900","DOI":"10.1073\/pnas.1901841116","article-title":"Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b","volume":"116","author":"Sharp","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jaut.2024.103305_bib146","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2015.11.010","article-title":"Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy","volume":"290","author":"Stork","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2024.103305_bib147","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jns.12291","article-title":"IqYmune\u00ae is an effective maintenance treatment for multifocal motor neuropathy: a randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig\u00ae-The LIME Study","volume":"24","author":"L\u00e9ger","year":"2019","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"10.1016\/j.jaut.2024.103305_bib148","doi-asserted-by":"crossref","first-page":"e1979","DOI":"10.1212\/WNL.0000000000010538","article-title":"Clinical outcomes in multifocal motor neuropathy: a combined cross-sectional and follow-up study","volume":"95","author":"Herraets","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib149","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1007\/s00415-018-9071-9","article-title":"Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment","volume":"265","author":"L\u00f6scher","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib150","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1529-8027.2010.00270.x","article-title":"An open-label trial of rituximab (Rituxan\u00ae) in multifocal motor neuropathy","volume":"15","author":"Chaudhry","year":"2010","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"10.1016\/j.jaut.2024.103305_bib151","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2024.103305_bib152","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/IAI.72.4.2148-2151.2004","article-title":"Normally occurring human anti-GM 1 immunoglobulin M antibodies and the immune response to bacteria","volume":"72","author":"Alaniz","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jaut.2024.103305_bib153","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-5728(02)00139-X","article-title":"High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies","volume":"128","author":"Lopez","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2024.103305_bib154","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1007\/s00415-022-11139-2","article-title":"Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy","volume":"269","author":"Bardel","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jaut.2024.103305_bib155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib156","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103305_bib157","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/WNL.0000000000011324","article-title":"The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy","volume":"96","author":"Vallat","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103305_bib158","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","article-title":"Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.jaut.2024.103305_bib159","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-023-01472-y","article-title":"A gene signature can predict risk of MGUS progressing to multiple myeloma","volume":"16","author":"Sun","year":"2023","journal-title":"J. Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.jaut.2024.103305_bib160","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood.2020004918","article-title":"MYD88 L265P elicits mutation-specific ubiquitination to drive NF-\u03baB activation and lymphomagenesis","volume":"137","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103305_bib161","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219825","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"6","author":"Nelde","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaut.2024.103305_bib162","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jaut.2024.103305_bib163","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002410","article-title":"High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies","volume":"9","author":"\u00c7\u0131nar","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T11:40:50Z","timestamp":1738496450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":163,"alternative-id":["S0896841124001392"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103305","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potentials of adoptive cell therapy in immune-mediated neuropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103305"}}